Solriamfetol ($ Sunosi)
Novel (dopamine-norepinephrine reuptake inhibition)
- ADHD3
- Sleep apnea (fatigue)2
- Narcolepsy
- Similar properties to buproprion
Features
Dosing
Start 37.5-75mg qam, raise every 3-7 days raise toward 75-150 mg qam.
Do not give within 9 hours of sleep. Half-life 7 hours. Schedule IV control.
Management
TOLERABILITY: Well tolerated (4% chance of anxiety, irritability, or insomnia; also headache, nausea, and low appetite.
RISKS: Mania.
EMR Text
ADHD
Solriamfetol use based on a randomized controlled trial in ADHD (Surman CBH et al, J Clin Psychiatry. 2023;84(6):23m14934).
Solriamfetol side effects reviewed with patient.